
Pinkus Tober-Lau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9864570/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	AÂsurvey among physicians in surgery and anesthesiology departments after the first surge of SARS-CoV-2 infections in Germany. Wiener Klinische Wochenschrift, 2022, 134, 361-370.	1.9	1
2	Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19. Diabetes Care, 2022, 45, 692-700.	8.6	40
3	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
4	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature Medicine, 2022, 28, 477-480.	30.7	342
5	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 2022, 185, 493-512.e25.	28.9	122
6	Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. Lancet Infectious Diseases, The, 2022, 22, 445-446.	9.1	28
7	Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging Infectious Diseases, 2022, 28, 1050-1052.	4.3	11
8	A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. EClinicalMedicine, 2022, 49, 101495.	7.1	17
9	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection, 2021, 49, 703-714.	4.7	27
10	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology, 2021, 12, 690698.	4.8	52
11	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clinical Microbiology and Infection, 2021, 27, 1520.e7-1520.e10.	6.0	13
12	A serum proteome signature to predict mortality in severe COVID-19 patients. Life Science Alliance, 2021, 4, e202101099.	2.8	62
13	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	6.2	125
14	Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021. Emerging Infectious Diseases, 2021, 27, 2169-2173.	4.3	17
15	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1255-1265.	10.7	279
16	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging Infectious Diseases, 2021, 27, 2174-2178.	4.3	67
17	Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. Lancet Respiratory Medicine,the, 2021, 9, e104-e105.	10.7	65
18	Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI. Journal of the American Society of Nephrology: JASN, 2020, 31, 2725-2735.	6.1	93

#	Article	IF	CITATIONS
19	Brain magnetic resonance imaging in imported malaria. Malaria Journal, 2019, 18, 74.	2.3	8